BridgeBio is substantially advanced its development of a new treatment for cardiac amyloidosis, utilizing the compound. Preliminary patient data reveals significant outcomes for those suffering with this severe disease. https://biotech314527.yomoblog.com/49528226/company-progresses-amyloidosis-therapy-through-the-therapy